Shorter course of less-intensive treatment for visceral leishmaniasis
1 February 2023. Related: Coinfections and complications.
Simon Collins, HIV i-Base
Results from an international study published in CID report better outcomes for treating visceral leishmaniasis with a daily combination of paromomycin and miltefosine for 14 days compared to twice-daily injections of sodium stibogluconate and paromomycin for 17 days. [1]
The reduced course had fewer daily injections and was also safer.
These findings have already been included in WHO guidelines and other information related to coinfection of HIV and visceral leishmaniasis. [2, 3]
The study was supported by both MSF and DNDi.
References
- Musa AM et al. Paromomycin and miltefosine combination as an alternative to treat patients with visceral leishmaniasis in eastern africa: a randomized, controlled, multicountry trial, Clinical Infectious Diseases, 2022;, ciac643, https://doi.org/10.1093/cid/ciac643
- WHO newsroom. Leishmaniasis. 12 January 2023
https://www.who.int/news-room/fact-sheets/detail/leishmanias - WHO. WHO publishes guideline on visceral leishmaniasis and HIV coinfection. (21 June 2022)
https://www.hps.scot.nhs.uk/publications/hps-weekly-report/volume-56/issue-24/who-publishes-guideline-on-visceral-leishmaniasis-and-hiv-coinfection/